Baiaoyi Pharma Announces RMB 27 Million Strategic Investment in SigeGene to Expand into Small Nucleic Acid Therapeutics

China Interview Network DataQingdaoBaiyang PharmaceuticalSicagen (Beijing) Biotechnology Co., Ltd. held the fifth meeting of the fourth board of directors on March 19, 2026, and reviewed and approved the proposal for external investment and related party transactions. According to the proposal, in order to expand the business layout in the field of small nucleic acid drugs, the company plans to invest RMB 27 million in cash into SicaGene (Beijing) Biotechnology Co., Ltd. After the completion of this investment, Baiyang Pharmaceutical will hold 10% of SicaGene's equity. This transaction constitutes a related party transaction, and the directors concerned have abstained from voting during the board review. This investment aims to enter the innovative drug technology field with development potential through equity investment, which is an important strategic measure for the company to improve its industrial ecology and explore new growth points.